Aspen Aerogels stock hits 52-week low at $5.03

Published 07/04/2025, 16:32
Aspen Aerogels stock hits 52-week low at $5.03

Aspen Aerogels Inc . (NYSE:ASPN) stock has reached a new 52-week low, trading at $5.03, signaling a period of significant bearish momentum for the company. According to InvestingPro data, technical indicators suggest the stock is in oversold territory, with a beta of 2.35 indicating higher volatility than the broader market. Despite the recent decline, the company maintains strong liquidity with a current ratio of 3.72. This latest price level reflects a stark contrast to the stock's performance over the past year, with Aspen Aerogels experiencing a substantial decline of -69.15% in its market value. The company, currently valued at $434 million, has shown impressive revenue growth of nearly 90% over the last twelve months. InvestingPro analysis indicates the stock may be slightly undervalued at current levels, with 13 additional exclusive insights available for subscribers. Investors are closely monitoring the stock as it navigates through this trough, considering the broader implications it may have on the company's financial health and future prospects.

In other recent news, Aspen Aerogels reported strong fourth-quarter 2024 earnings, exceeding analyst expectations with an earnings per share (EPS) of $0.14 against a forecast of $0.08. The company also reported revenue of $123.1 million, surpassing the anticipated $114.42 million, marking a 46% year-over-year revenue growth. Despite these positive results, the company's stock declined significantly in after-hours trading. Additionally, Aspen Aerogels introduced performance-based equity awards for its executives, aligning their interests with shareholders by tying rewards to stock performance relative to the Russell 2000 Index over three years. Analysts have also revised their outlooks on the company, with TD Cowen initiating coverage with a Buy rating and an $11 price target, citing the company's strong gross margins and alignment with growing U.S. electric vehicle demand. Conversely, Barclays (LON:BARC) and Oppenheimer lowered their price targets to $13, maintaining Overweight and Outperform ratings, respectively, due to changing market dynamics and revised production forecasts. These developments reflect Aspen Aerogels' strategic focus on cost reduction and modular capacity expansion in response to evolving market conditions.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.